This research aimed to investigate how TILs and PD-L1 expression in paired tissues changed prior to and following NAT, as well as the relationship between these improvements and the effectiveness of neoadjuvant trastuzumab plus chemotherapy in HER2-positive breast cancer patients. Here, ERBB2 is linked to breast carcinoma.